Detalles de la búsqueda
1.
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
BMC Med
; 21(1): 164, 2023 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37118803
2.
SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy.
BMC Cancer
; 23(1): 686, 2023 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479966
3.
Porous Pure MXene Fibrous Network for Highly Sensitive Pressure Sensors.
Langmuir
; 38(18): 5494-5501, 2022 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35452246
4.
Highly Transparent and Flexible Zn-Ti3C2Tx MXene Hybrid Capacitors.
Langmuir
; 38(19): 5968-5976, 2022 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35522587
5.
Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Anticancer Drugs
; 29(10): 935-943, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30074936
6.
Intracranial response pattern, tolerability and biomarkers associated with brain metastases in non-small cell lung cancer treated by tislelizumab plus chemotherapy.
Transl Lung Cancer Res
; 13(2): 269-279, 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38496686
7.
Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study.
J Clin Oncol
; : JCO2400731, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38822758
8.
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
J Thorac Oncol
; 19(2): 314-324, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37776953
9.
Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report.
Front Med (Lausanne)
; 10: 1168220, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37457583
10.
The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
Front Immunol
; 14: 1218258, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37614237
11.
Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review.
Front Oncol
; 13: 1126325, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36910616
12.
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Lung Cancer
; 184: 107355, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37677918
13.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
EClinicalMedicine
; 62: 102106, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37593227
14.
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Signal Transduct Target Ther
; 8(1): 301, 2023 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37574511
15.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Cancer Cell
; 41(6): 1061-1072.e4, 2023 06 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207654
16.
The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching.
J Cancer
; 13(1): 51-61, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34976170
17.
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.
Front Oncol
; 12: 1054593, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36505860
18.
The Effect of PD-1 Inhibitor Combined with Chemotherapy on the Level of Peripheral Blood T Lymphocytes among Patients with Non-Small-Cell Lung Cancer and Its Relationship with Prognosis.
Comput Math Methods Med
; 2022: 1679191, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36118825
19.
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.
Lung Cancer
; 171: 56-60, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35917647
20.
Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
J Clin Invest
; 132(20)2022 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36048538